Andy Evans, Macclesfield Site Manager at AstraZeneca and Chair of the Medicines Manufacturing Industry Partnership has responded to the proposal in the Budget for investment in medicine manufacturing technologies.
This investment comes from the part of the first phase of the "Industrial Strategy Challenge Fund", which sets aside £270m for research in the field, alongside robotics and next-generation batteries.
"We welcome the Government's recognition in the Budget of the potential of new medicines manufacturing technologies, as well as the promise of Advanced Therapies. We look forward to working with Government to develop the detail of how these technologies will be supported.
"The next generation of medicines, including medicines tailored to individual patients and cell and gene therapies, are already here. The UK has played a leading role in researching and developing these therapies. This commitment from Government is a welcome first step in ensuring that the UK economy benefits from the manufacture of these medicines, the next important step will be to see patients in the UK benefitting from their potential."
ABPI Press OfficeEmail: firstname.lastname@example.orgTelephone during work hours (9am to 5pm Monday to Friday):+44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends):+44 (0) 20 7747 1445
The Medicines Manufacturing Industry Partnership (MMIP) represents the voice of medicines manufacturers in the UK. It was established jointly by Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class, advanced centre for medicines manufacturing. MMIP is supported by the Association of the British Pharmaceutical Industry (ABPI), the BioIndustry Association (BIA) and Knowledge Transfer Network (KTN), and includes leadership from Allergan Biologics, AstraZeneca, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Pfizer and ReNeuron.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.